Rucaparib: Additional Phase II data

Data from 15 evaluable platinum-sensitive, relapsed ovarian cancer patients with germline breast cancer early onset (BRCA) mutations in the Phase II portion of an open-label, U.S. and U.K. Phase I/II trial showed that twice-daily 600 mg oral rucaparib led to a disease control rate (DCR) of 93%, including 12 partial responses. Additionally, rucaparib led to target lesion regressions in 16 of 17 evaluable patients and CA-125 reductions in 12 of 14 evaluable patients with elevated CA-125 levels at baseline. Data were presented at the European Society for Medical Oncology meeting in Madrid. Clovis previously reported preliminary data from the Phase II portion of the trial and final data from the Phase I portion (see BioCentury, June 10, 2013 & July 21, 2014). ...